Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1975 3
1976 3
1977 1
1978 4
1979 2
1980 6
1981 6
1982 15
1983 11
1984 11
1985 17
1986 23
1987 25
1988 24
1989 46
1990 21
1991 24
1992 24
1993 22
1994 22
1995 18
1996 26
1997 19
1998 22
1999 14
2000 15
2001 6
2002 12
2003 12
2004 18
2005 17
2006 16
2007 7
2008 11
2009 9
2010 21
2011 34
2012 36
2013 33
2014 34
2015 45
2016 68
2017 65
2018 73
2019 65
2020 53
2021 41
2022 21
2023 26
2024 53
2025 95
2026 41

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,237 results

Results by year

Filters applied: . Clear all
Page 1
Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.
Hoy SM. Hoy SM. Drugs. 2019 Oct;79(15):1709-1718. doi: 10.1007/s40265-019-01201-1. Drugs. 2019. PMID: 31549300 Review.
An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa( ) (EU); Duopa (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with o …
An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbi …
Diagnosis and Treatment of Parkinson Disease: A Review.
Armstrong MJ, Okun MS. Armstrong MJ, et al. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. JAMA. 2020. PMID: 32044947 Review.
Individuals with mild motor-predominant Parkinson disease (49%-53% of individuals with Parkinson disease) have mild symptoms, a good response to dopaminergic medications (eg, carbidopa-levodopa, dopamine agonists), and slower disease progression. Other individuals h …
Individuals with mild motor-predominant Parkinson disease (49%-53% of individuals with Parkinson disease) have mild symptoms, a good respons …
24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations.
Thakkar S, Fung VSC, Merola A, Rollins M, Soileau MJ, Kovács N. Thakkar S, et al. CNS Drugs. 2021 Feb;35(2):137-149. doi: 10.1007/s40263-020-00782-w. Epub 2021 Feb 13. CNS Drugs. 2021. PMID: 33582982 Free PMC article. Review.
Infusion of levodopa-carbidopa intestinal gel (LCIG; also designated carbidopa-levodopa enteral suspension) for 16 hours is a standard treatment for patients with advanced Parkinson's disease, and clinical observations suggest that 24-hour LCIG infusio …
Infusion of levodopa-carbidopa intestinal gel (LCIG; also designated carbidopa-levodopa enteral suspension) for …
Carbidopa/Levodopa ER Capsules (Rytary( ), Numient ): A Review in Parkinson's Disease.
Greig SL, McKeage K. Greig SL, et al. CNS Drugs. 2016 Jan;30(1):79-90. doi: 10.1007/s40263-015-0306-3. CNS Drugs. 2016. PMID: 26692288 Review.
The efficacy of carbidopa/levodopa ER was maintained during a 9-month open-label extension in patients with early or advanced PD. ...Thus, carbidopa/levodopa ER is an effective and generally well-tolerated treatment option for the motor symptoms of PD, …
The efficacy of carbidopa/levodopa ER was maintained during a 9-month open-label extension in patients with early or advanced …
Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease.
Müller T, Möhr JD. Müller T, et al. Expert Opin Pharmacother. 2018 Dec;19(18):2063-2071. doi: 10.1080/14656566.2018.1538355. Epub 2018 Nov 5. Expert Opin Pharmacother. 2018. PMID: 30396279 Review.
Areas covered: This non-systematic, narrative drug evaluation brings the therapeutic value of IPX066 up for discussion. IPX066 is an orally applied levodopa/carbidopa containing formulation with modified drug release. It is rapidly absorbed, similar to conventional …
Areas covered: This non-systematic, narrative drug evaluation brings the therapeutic value of IPX066 up for discussion. IPX066 is an orally …
Pharmacokinetics of Rytary( ), An Extended-Release Capsule Formulation of Carbidopa-Levodopa.
Mittur A, Gupta S, Modi NB. Mittur A, et al. Clin Pharmacokinet. 2017 Sep;56(9):999-1014. doi: 10.1007/s40262-017-0511-y. Clin Pharmacokinet. 2017. PMID: 28236251 Free PMC article. Review.
Phase III studies of this ER carbidopa-levodopa capsule formulation in patients with PD have shown a significant reduction in 'off' time compared with IR carbidopa-levodopa and carbidopa-levodopa-entacapone. We present a review of the cli …
Phase III studies of this ER carbidopa-levodopa capsule formulation in patients with PD have shown a significant reduction in …
Parkinson Disease.
Halli-Tierney AD, Luker J, Carroll DG. Halli-Tierney AD, et al. Am Fam Physician. 2020 Dec 1;102(11):679-691. Am Fam Physician. 2020. PMID: 33252908 Free article.
Therapies, including levodopa, have not demonstrated the ability to slow disease progression. Motor symptoms are managed with carbidopa/levodopa, monoamine oxidase-B inhibitors, and nonergot dopamine agonists. Prolonged use and higher doses of levodopa result in dys …
Therapies, including levodopa, have not demonstrated the ability to slow disease progression. Motor symptoms are managed with carbidopa …
Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis.
Standaert DG, Patel V, Snedecor SJ, Thakkar S, Jalundhwala YJ, Kukreja P, Kratochvil D, Bao Y, Pahwa R. Standaert DG, et al. Parkinsonism Relat Disord. 2021 May;86:52-57. doi: 10.1016/j.parkreldis.2021.03.009. Epub 2021 Mar 23. Parkinsonism Relat Disord. 2021. PMID: 33857722 Free article.
INTRODUCTION: To estimate the impact of carbidopa/levodopa enteral suspension (CLES) on key patient-centered outcomes in patients with advanced Parkinson's disease (PD). ...
INTRODUCTION: To estimate the impact of carbidopa/levodopa enteral suspension (CLES) on key patient-centered outcomes in patie …
Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Amjad F, Bhatti D, Davis TL, Oguh O, Pahwa R, Kukreja P, Zamudio J, Metman LV. Amjad F, et al. Adv Ther. 2019 Sep;36(9):2233-2246. doi: 10.1007/s12325-019-01014-4. Epub 2019 Jul 5. Adv Ther. 2019. PMID: 31278691 Free PMC article. Review.
In 2015, the US Food and Drug Administration approved levodopa-carbidopa intestinal gel (LCIG; also known as carbidopa-levodopa enteral suspension in the US) for the treatment of motor fluctuations in patients with advanced Parkinson's disease. ...LCIG …
In 2015, the US Food and Drug Administration approved levodopa-carbidopa intestinal gel (LCIG; also known as carbidopa- …
1,237 results